Digital CBT-I in Comorbid Insomnia and Depression: Clinical Outcomes From a Pragmatic Randomized Controlled Trial.

Depress Anxiety

Department of Clinical Psychology, Institute of Experimental Psychology, Heinrich Heine University, Universitätsstraße 1, Düsseldorf 40225, Germany.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Depression affects 8.1% of the German population annually, yet many patients remain resistant to conventional treatments. Given that 85% of individuals with depression also experience chronic insomnia, sleep may represent both a contributing and modifiable treatment factor. This study examines whether adding a fully automated digital cognitive behavioral therapy for insomnia (dCBT-I) to care-as-usual (CAU) improves depressive symptoms. Participants with comorbid depression and insomnia were randomized to either the intervention group (dCBT-I) or the waiting group (WLC). The intervention was delivered via a mobile app or web platform, consisting of 10 sequential core modules based on evidence-based CBT-I techniques. Assessments took place at baseline, 12- and 24-weeks post randomization. The primary outcome was the severity of depressive symptoms (Patient Health Questionnaire-9; PHQ-9). Secondary outcomes included insomnia severity, daytime sleepiness, fatigue, well-being and mechanistic effect measures. Linear mixed models were calculated to determine between-group effects. A total of 140 participants (120 women, mean age:  = 39.76 ± 11.65 years) were randomized to dCBT-I (=70) or WLC (=70). Large treatment effects at 12- and 24 weeks showed significant reductions in depressive symptoms (-3.34 and -2.83; s <0.001; s = 0.66-0.78) in the dCBT-I group. Treatment effects in favor of dCBT-I were also found for insomnia severity (s = 1.46-1.94) and most secondary outcomes (s = 0.33-1.14). This study demonstrates that digital dCBT-I can be effective not only for individuals with primary insomnia but also for those with depression. These findings align with previous research, highlighting the crucial role of sleep disturbances in depression management. Moreover, the effects remained stable even in the heterogeneous sample investigated in this study, reinforcing the robustness of dCBT-I across diverse patient groups. Thus, dCBT-I emerges as a promising adjunctive treatment. Considering these findings, it is essential to explore the integration of sleep-focused interventions into standard depression treatment. German Clinical Trial Registry identifier: DRKS00030919.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129620PMC
http://dx.doi.org/10.1155/da/2171041DOI Listing

Publication Analysis

Top Keywords

depressive symptoms
12
insomnia
5
digital cbt-i
4
cbt-i comorbid
4
comorbid insomnia
4
depression
4
insomnia depression
4
depression clinical
4
clinical outcomes
4
outcomes pragmatic
4

Similar Publications

Background: The loss of a loved one is a common yet stressful event in later life. Internet- and mobile-based interventions have been proposed as an effective treatment approach for individuals with prolonged grief.

Objective: The AgE-health study aimed to investigate the efficacy of an eHealth intervention, trauer@ktiv, in reducing prolonged grief symptoms in a sample of older adults.

View Article and Find Full Text PDF

Importance: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress; however, access to psychological support remains limited.

Objective: To investigate the effectiveness of a digital psychological intervention for individuals with IRDs.

Design, Setting, And Participants: Participants aged 18 years or older were recruited across Germany between February 22 and June 4, 2024, if they had been diagnosed with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus and reported psychological distress and reduced quality of life.

View Article and Find Full Text PDF

Guided by the Ottawa Decision Support Framework, we created a depression care decision aid for Latinx and African American individuals with major depressive disorder (MDD) at a network of Federally Qualified Health Centers. We surveyed 94 African American and Latinx individuals with MDD about their decision making needs. Focus groups elaborated on these preferences.

View Article and Find Full Text PDF

Objectives: Patients diagnosed with amyotrophic lateral sclerosis (ALS) typically describe symptoms of fatigue. Despite this frequency, the underlying mechanisms of fatigue are poorly understood, and are likely multifactorial. To help clarify mechanisms, the present systematic review was undertaken to determine the risk factors related to fatigue in ALS.

View Article and Find Full Text PDF

This study aimed to evaluate the antidepressant potential of Nitazoxanide (NTZ), an antiprotozoal drug with known anti-inflammatory and neuroprotective properties, in a chronic unpredictable mild stress (CUMS)-induced mice model of depression. NTZ was administered at doses of 75, 150, and 300 mg/kg, and its effects were assessed through a series of behavioral tests, including the forced swim test, tail suspension test, actophotometer test, and social interaction test. NTZ treatment at 150 and 300 mg/kg significantly improved behavioral and biochemical outcomes, relieving depressive-like symptoms and restoring neurochemical balance.

View Article and Find Full Text PDF